News | July 21, 2022
Syngene reports revenue from operations up 8% in Q1 FY 23
Company raises the annual revenue guidance from mid-teens to high teens
Company raises the annual revenue guidance from mid-teens to high teens
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
Tobacco smoke increases infant morbidity and is fatal to a baby because it damages the baby’s organs
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Syngene's collaboration with Zoetis started in 2011
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
Subscribe To Our Newsletter & Stay Updated
